Recurrent epithelial ovarian cancer and hormone therapy  

作　　者：Yoshihito Yokoyama Hideki Mizunuma 

机构地区：[1]Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Hirosaki 036-8652, Japan

出　　处：《World Journal of Clinical Cases》2013年第6期187-190,共4页世界临床病例杂志

基　　金：Supported by The Karoji Memorial Fund of the Hirosaki University Graduate School of Medicine

摘　　要：The role of hormone therapy in the treatment of ovarian cancer is not clear. Data on the efficacy and safety of antiestrogens and aromatase inhibitors in recurrent ovarian cancer have been accumulated through phase Ⅱ clinical studies. Most of these studies were conducted in platinum-resistant recurrent ovarian cancer, and although complete response rates were not high, reported adverse events were low. If administered to patients who are positive for estrogen receptors, hormone therapy may become a viable option for the treatment of recurrent ovarian cancer.The role of hormone therapy in the treatment of ovarian cancer is not clear. Data on the efficacy and safety of antiestrogens and aromatase inhibitors in recurrent ovarian cancer have been accumulated through phase Ⅱ clinical studies. Most of these studies were conducted in platinum-resistant recurrent ovarian cancer, and although complete response rates were not high, reported adverse events were low. If administered to patients who are positive for estrogen receptors, hormone therapy may become a viable option for the treatment of recurrent ovarian cancer.

关 键 词：Recurrent OVARIAN cancer HORMONE therapy LETROZOLE ANASTROZOLE TAMOXIFEN FULVESTRANT 

分 类 号：R737.31[医药卫生—肿瘤]